The efficacy and safety of terazosin for the treatment of symptomatic BPH

@article{Lepor1991TheEA,
  title={The efficacy and safety of terazosin for the treatment of symptomatic BPH},
  author={Herbert Lepor and Dan C. Henry and A. R. Laddu},
  journal={The Prostate},
  year={1991},
  volume={18}
}
At least 16 clinical investigations have documented the effectiveness of alpha blockade for BPH. In the present review, four clinical studies evaluating the efficacy and safety of terazosin, a selective long‐acting alpha1 blocker, for symptomatic BPH are reviewed. The unique features of these clinical investigations are: the study designs established detailed inclusion and exclusion criteria, the outcome assessments were based upon quantitative outcome parameters, large cohorts of homogeneous… Expand
42 Citations

Paper Mentions

Interventional Clinical Trial
The Medical Therapy of Prostatic Symptoms (MTOPS) is a clinical research study sponsored by the National Institutes of Health (NIH). The study will test whether the oral drugs… Expand
ConditionsProstatic Hyperplasia, Prostatic Hypertrophy, Benign
InterventionDrug
The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia.
TLDR
The study demonstrates the safety, efficacy and compliance of terazosin therapy for BPH during a 2-year followup. Expand
Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia*
TLDR
This study suggests that terazosin is well tolerated and effective in long-term treatment of patients with BPH, with peak urinary flow rates significantly higher than baseline values. Expand
A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia.
TLDR
This study unequivocally demonstrates the safety and efficacy of terazosin for the treatment of symptomatic BPH, and selective alpha 1-blockade is likely to gain widespread acceptance for the Treatment of BPH due to itssafety and efficacy. Expand
The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.
TLDR
Terazosin given once daily in a dose ranging from 2 to 10 mg in community-based urology practices under conditions simulating usual care is effective in reducing the symptoms, perception of bother, and the impairment of QQL due to urinary symptoms in men with moderate to severe symptoms of prostatism. Expand
Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trial.
TLDR
Terazosin was well tolerated by patients in this study and may provide symptomatic relief in patients with BPH and was well administered in a multicentre, randomised, placebo-controlled trial involving patients with symptomatic bladder outflow obstruction. Expand
Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial.
TLDR
The design of the MTOPS trial, the concept of BPH progression, the definition and methods of determining the primary outcome events and the proposed statistical analysis methods are described. Expand
Terazosin in benign prostatic hyperplasia: effects on blood pressure in normotensive and hypertensive men.
  • R. Kirby
  • Medicine
  • British journal of urology
  • 1998
TLDR
Terazosin is a safe treatment for BPH in normotensive and hypertensive men, including men who are already taking additional antihypertensive drugs, and it did not adversely affect patients receiving concomitant anti Hypertensive medication. Expand
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia.
TLDR
Overall, this study showed terazosin to be safe and effective in relieving the signs and symptoms of BPH and should be considered as a treatment alternative. Expand
The emerging role of alpha antagonists in the therapy of benign prostatic hyperplasia.
  • H. Lepor
  • Medicine
  • Journal of andrology
  • 1991
TLDR
The preliminary experiences with alpha blockers for the treatment of BPH has been very encouraging, yet, the definitive role of alpha blockade in BPH awaits the reporting of multicenter, randomized placebo-controlled studies. Expand
Long-term drug treatment of benign prostatic hyperplasia - results of a prospective 3-year multicenter study using Sabal extract IDS 89.
  • D. Bach, L. Ebeling
  • Medicine
  • Phytomedicine : international journal of phytotherapy and phytopharmacology
  • 1996
TLDR
The clinical status of BPH and thus the quality of life of 4 out of 5 patients was markedly improved by long-term IDS 89 therapy and the deterioration rate at the end of the 3-year treatment period was significantly lower than in untreated BPH subjects. Expand
...
1
2
3
4
5
...

References

SHOWING 1-8 OF 8 REFERENCES
Role of alpha‐adrenergic blockers in the treatment of benign prostatic hyperplasia
  • H. Lepor
  • Medicine
  • The Prostate. Supplement
  • 1990
TLDR
The dynamic component of infravesical obstruction in men with symptomatic benign prostatic hyperplasia (BPH) is determined by alpha1‐adrenoceptor‐mediated contractions of the prostatic capsule, prostate adenoma, and bladder neck, and medical therapy aimed at blocking the alpha receptor will relieve bladder outlet obstruction without inhibiting bladder function. Expand
Pharmacology of terazosin.
  • J. Kyncl
  • Medicine
  • The American journal of medicine
  • 1986
TLDR
Comparison of the oral activity of terazosin in spontaneously hypertensive rats with the oral toxicity values in normal rats revealed a high efficacy/safety ratio and the nature of the alpha-blocking properties of terrazosin was evaluated in vitro using both radioligand binding studies and functional tests in rabbit aorta and pulmonary artery, demonstrating that terazOSin is highly selective for alpha1 receptors. Expand
Efficacy of once‐A‐day terazosin in benign prostatic hyperplasia: A randomized, double‐blind placebo‐controlled clinical trial
This randomized, placebo‐controlled, double‐blind study was performed to evaluate the efficacy and safety of once‐a‐day terazosin (10 mg/day) in ambulatory patients (n = 57) with benign prostaticExpand
Efficacy and safety of diclofenac sodium in rheumatoid arthritis. Experience in the United States.
  • J. Caldwell
  • Medicine
  • The American journal of medicine
  • 1986
Diclofenac sodium is a nonsteroidal, anti-inflammatory drug that has been studied in the United States for the treatment of rheumatoid arthritis in 681 patients, 468 of whom were enrolled in fiveExpand
The use of alpha-adrenergic blockers in benign prostatic obstruction.
TLDR
It is emphasised that this treatment provides symptomatic relief only, and in no sense purports to be a treatment of the enlarged prostate itself. Expand
Evaluation of treatment response to drugs in benign prostatic hyperplasia.
  • A. Wein
  • Medicine
  • The Urologic clinics of North America
  • 1990
Relevant factors, both simple and complicated, for the evaluation of the treatment of outlet obstruction secondary to BPH have been discussed in the context of defining the components of an adequateExpand
Determination of norepinephrine levels in the adult human prostate.
TLDR
The relatively low level of norepinephrine in the specimens obtained from patients with symptoms necessitating prostatectomy provides further evidence that norpinephrine levels are inversely related to the degree of symptomatic bladder outlet obstruction. Expand
Striated sphincter participation in distal passive urinary continence mechanisms: studies in male subjects deprived of proximal sphincter mechanism.
TLDR
The studies indicate that the participating role of periurethral striated musculature in distal passive continence mechanisms cannot be ignored. Expand